Barry P. King

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

Elizabeth Sconce, Tayyaba Khan, Hilary Wynne et al. · Blood · 2005 · 945 citations · Full text

Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2

Éric Thervet, Dany Anglicheau, Barry P. King et al. · Transplantation · 2003 · 298 citations

Contribution of age, body size, and <i>CYP2C9</i> genotype to anticoagulant response to warfarin

Farhad Kamali, Tayyaba Khan, Barry P. King et al. · Clinical Pharmacology & Therapeutics · 2004 · 217 citations

Upstream and coding region CYP2C9 polymorphisms

Barry P. King, Tayyaba Khan, Guruprasad P. Aithal et al. · Pharmacogenetics · 2004 · 91 citations

CYP3A5 phenotype‐genotype correlations in a British population

Barry P. King, Julian Leathart, Elaine Mutch et al. · British Journal of Clinical Pharmacology · 2003 · 74 citations · Full text